Adoption of AI in precision medicine depends on clinical value and on practical barriers such as data governance and system integration. Polaris Market Research valued the Artificial Intelligence in Precision Medicine Market at USD 2.53 billion in 2025 and projects USD 38.88 billion by 2034, a CAGR of 35.5% from 2026 to 2034, with North America the largest region in 2025. This article looks at where AI is being applied clinically and what could slow adoption.
Oncology Leads Therapeutic Applications
By therapeutic application, the report covers oncology, cardiology, neurology, respiratory and others. Oncology held the largest share, at 42.6% in 2025, while neurology is the fastest-growing segment, at a 36.9% CAGR from 2026 to 2034. The page cites research suggesting better survival rates in some cancers with precision approaches. Recent launches reflect the focus on oncology: in February 2026, Tempus AI launched its HRD-RNA algorithm, which identifies cancer patients likely to benefit from PARP inhibitors and platinum therapies, and in May 2026, Myriad Genetics launched Prolaris + AI, combining genomics and digital pathology AI for prostate cancer risk assessment.
Demand for Personalized Treatment
A major driver is rising demand for personalized medicine, as patients and providers look for treatments tailored to genetics, lifestyle and environment. The page lists demand for AI-driven, individualized treatment plans among the trends, and its outlook expects wider adoption of AI-based personalized treatment in hospitals and research centers. For vendors, personalized treatment use cases give a clear route to demonstrating clinical relevance. For new entrants, the page suggests focusing on AI genomic analysis and personalized treatment tools, targeting niche areas such as rare diseases, and partnering with providers and pharma for clinical validation.
Integration With Health Data Systems
Practical integration is a recurring theme. Among the page's suggestions for new entrants is to integrate with electronic health records and wearables, and its restraints include limited interoperability with existing healthcare systems. Providers evaluating AI tools should therefore ask how each product connects with electronic health records and other clinical data sources, since interoperability appears on the page as a limiting factor.
Data Privacy, Regulation and Cost
The report is explicit about barriers. Data privacy concerns and regulatory challenges limit adoption, and large volumes of patient and genomic data create data privacy and security risks. Other restraints include high implementation costs for software, infrastructure and skilled staff, regulatory complexity with differing rules across countries, and model bias from limited or unbalanced training data. A lack of awareness and skilled professionals is listed in the table of contents. Vendors that address data privacy and security early, and prioritize regulatory compliance as the page advises new entrants to do, are better positioned to earn the trust of providers.
𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:
Evaluating Vendors on Adoption Readiness
Providers can turn these barriers into an evaluation framework. Questions worth asking include how a tool connects with existing health data systems, how patient and genomic data are protected, how the vendor addresses model bias, and what implementation costs cover, including software, infrastructure and skilled staff. Vendors able to answer clearly, and to show clinical validation with provider and pharma partners, will find adoption conversations easier.
Outlook: Multimodal AI and Digital Twins
Looking ahead, the page points to growth tied to genomics and multi-omics data, integration with digital health platforms and wearables, advances in multimodal AI models and digital twins, and a greater focus on predictive and preventive care. These developments suggest that digital twins and related tools will be part of future evaluation criteria for health systems and research centers.
Regional Adoption and Partnerships
North America held a 43.3% share in 2025, while Asia Pacific is the fastest-growing region at a 37.4% CAGR from 2026 to 2034. Europe is described as steadily growing, with the UK, Germany and France named as leaders in adoption, and the EU's digital health and AI regulatory focus is noted. In April 2025, Illumina and Tempus AI formed a strategic partnership to speed clinical adoption of next-generation sequencing tests.
Key Players
The report names IBM Corporation; Microsoft Corporation; Google Health; NVIDIA Corporation; Tempus Labs; Zebra Medical Vision; Butterfly Network; PathAI; BenevolentAI; Recursion Pharmaceuticals; Illumina; Siemens Healthineers; GE Healthcare; Philips Healthcare; and Foundation Medicine among the key players. The page says that growth strategies center on partnerships, collaborations, research and development, expansion into emerging markets, digital engagement and regulatory compliance. The page identifies the audience for such products as companies that manufacture, distribute or buy AI precision medicine products, as well as consulting firms. Its Porter's Five Forces ratings are moderate for supplier power, low for the threat of new entrants, moderate for buyer power and for the threat of substitutes, and high for rivalry among existing firms.
Conclusion
Clinical value is clearest in oncology, and demand for tailored care continues to build. Adoption, however, hinges on integration, governance and cost. Stakeholders in the Artificial Intelligence in Precision Medicine Market should weigh clinical evidence together with interoperability, compliance and implementation requirements when selecting partners.
More Trending Latest Reports By Polaris Market Research:
Lithium-Ion Battery Cathode Market
Next-Generation Sequencing Market